Literature DB >> 27259332

[Rare syndromes in intensive care medicine : Presentation of two cases].

A Gierlinger1, P Siostrzonek2, J Reisinger2.   

Abstract

This article presents two cases of young women with spontaneous life-threatening bleeding events. Both had a history of gastrointestinal rupture or arterial dissection. Based on their medical history and genetic testing, Ehlers-Danlos syndrome (EDS) IV (vascular type) was diagnosed. In this very rare disorder which accounts for only 5 % of all EDS cases, fibroblasts synthesize reduced and abnormal procollagen type III. This is caused by mutations in the COL3A1 gene coding for type III procollagen. Life expectancy in these patients is significantly reduced. In many cases spontaneous arterial ruptures or dissections and organ ruptures are the first manifestations of this disease. More than 80 % of patients with EDS IV suffer from a severe complication before 40 years of age. Treatment options are very limited. Most important is to avoid invasive procedures (open surgery as well as endovascular interventions) because of its high morbidity and mortality. Celiprolol, a cardioselective β‑blocker, seems to have a beneficial effect by reducing the incidence of vascular complications.

Entities:  

Keywords:  COL3A1 protein, human; Celiprolol; Ehlers–Danlos syndrome; Rupture, spontaneous; Vascular diseases

Mesh:

Year:  2016        PMID: 27259332     DOI: 10.1007/s00063-016-0167-7

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  14 in total

1.  Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK).

Authors:  P Beighton; A De Paepe; B Steinmann; P Tsipouras; R J Wenstrup
Journal:  Am J Med Genet       Date:  1998-04-28

2.  Vascular complications in the Ehlers-Danlos syndrome, with special reference to the "arterial type" or Sack's syndrome.

Authors:  A P Barabas
Journal:  J Cardiovasc Surg (Torino)       Date:  1972 Mar-Apr       Impact factor: 1.888

3.  Altered secretion of type III procollagen in a form of type IV Ehlers-Danlos syndrome. Biochemical studies in cultured fibroblasts.

Authors:  P H Byers; K A Holbrook; G S Barsh; L T Smith; P Bornstein
Journal:  Lab Invest       Date:  1981-04       Impact factor: 5.662

4.  Heterogeneity of the Ehlers-Danlos syndrome: description of three clinical types and a hypothesis to explain the basic defect(s).

Authors:  A P Barabas
Journal:  Br Med J       Date:  1967-06-03

5.  Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Authors:  Kim-Thanh Ong; Jérôme Perdu; Julie De Backer; Erwan Bozec; Patrick Collignon; Joseph Emmerich; Anne-Laure Fauret; Jean-Noël Fiessinger; Dominique P Germain; Gabriella Georgesco; Jean-Sebastien Hulot; Anne De Paepe; Henri Plauchu; Xavier Jeunemaitre; Stéphane Laurent; Pierre Boutouyrie
Journal:  Lancet       Date:  2010-09-07       Impact factor: 79.321

Review 6.  Vasculitis mimics.

Authors:  Eamonn S Molloy; Carol A Langford
Journal:  Curr Opin Rheumatol       Date:  2008-01       Impact factor: 5.006

Review 7.  Treatment of vascular Ehlers-Danlos syndrome: a systematic review.

Authors:  David Bergqvist; Martin Björck; Anders Wanhainen
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

8.  Patients with Ehlers-Danlos syndrome type IV lack type III collagen.

Authors:  F M Pope; G R Martin; J R Lichtenstein; R Penttinen; B Gerson; D W Rowe; V A McKusick
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

9.  Mitral valve prolapse: a consistent manifestation of type IV Ehlers-Danlos syndrome. The pathogenetic role of the abnormal production of type III collagen.

Authors:  A S Jaffe; E M Geltman; G E Rodey; J Uitto
Journal:  Circulation       Date:  1981-07       Impact factor: 29.690

Review 10.  Ehlers-Danlos syndrome type IV.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2007-07-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.